Caladrius doses first patient with CLBS12 in phase 2 critical limb ischemia trial
Caladrius announces that the first patient has been dosed in the Company’s Phase 2 clinical trial in Japan with its proprietary CD34 cell therapy (CLBS12) for the treatment of no-option critical limb ischemia. This trial is a 35-patient prospective, randomized, controlled, multicenter study. March 13, 2018
